HALOZYME THERAPEUTICS, INC. 8-K

What Happened
Halozyme Therapeutics, Inc. (HALO) filed a Form 8-K on February 17, 2026 to report its results of operations and financial condition for the quarter ended December 31, 2025. The company issued a press release with the quarterly results; that press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: February 17, 2026; reporting period: quarter ended December 31, 2025.
• Press release with the Q4 2025 results is attached as Exhibit 99.1 to the Form 8-K.
• The filing includes the interactive cover page XBRL data (inline XBRL referenced in the exhibits).
• The report is signed by Nicole LaBrosse, Senior Vice President and Chief Financial Officer.

Why It Matters
This 8-K formally notifies investors that Halozyme has released its quarterly earnings and related financial information. The press release will contain the key metrics retail investors care about—revenue, net income/loss, EPS, and any management commentary or guidance—so investors should read Exhibit 99.1 and any related SEC filings for the full numbers and context. Quarterly earnings reports can affect valuation and near-term stock performance, so review the detailed results and company commentary before making investment decisions.